Clinical Trial Update: A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/Phase 2 trial evaluating CDX-1401 in combination with Poly-ICLC and pembrolizumab for previously treated advanced solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Mesothelioma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Triple-negative Breast Cancer
• Urothelial Cancer

Drugs mentioned

• CDX-1401
• Pembrolizumab (pembrolizumab)
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: WITHDRAWN